Published on 27 February 2023
Description:
New PharmaTimes is out now, navigating the vast pharmaverse. This time we’re having a very honest conversation about the NHS – why it is failing, what the possible remedies for modernisation are and how it can thrive in the future. We are also focusing on precision medicine, health inequalities and prescribing trends.
Categories:
PharmaTimes27 articles from this collection:
Cover
2 - FlyPharma Europe
3 - From the editor
This month PharmaTimes presents Alantra’s annual ranking of the fastest growing pharma companies in the UK, and again there is much cause for celebration. As the analysis shows, a relentless focus on innovation and a determination to solve problems hindering patient outcomes are key traits that have helped those at the top shine in a sector that saw average growth of 33% in 2020.
4-5 - Contents
6 - NEWS: Treatments
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on the potential reclassification of two progestogen-only, oral contraceptive pills containing desogestrel: Lovima 75mcg and Hana 75mcg film-coated tablets.
7 - NEWS: Clinical Trials
8 - NEWS: Collaboration
9 - NEWS: Conditions
10-12 - COVER STORY: Winter of discontent
13 - D&I: Shining lights
14-15 - WOMEN’S HEALTH: Pause for thought
16 - AI: Ahead in the clouds
17 - D&I: Dimensions of difference
18-19 - NHS: Back to the future
20-21 - PRECISION MEDICINE: Love Hearts
22 - Communique Awards 23
23 - SUSTAINABILITY: Circle of life
24-25 - DATA: Challenge of our age
26-27 - DIGITAL: Transformers
28-29 - INDUSTRY ISSUE: Everything I own?
30-31 - PRESCRIBING: A nation prescribed
32-33 - D&I: We all stand together
34-35 - NHS: Difficult conversation
36-37 - Your moves
38 - THOUGHT LEADER: Thinking outside the box
39 - PHARMATIMES
40 - USCROY
PharmaTimes
PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.